Figure 3From: Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: a systematic review Cancer-specific survival. EST-3886, median follow-up 11.9Â years; AST, androgen suppression therapy. (This figure should be published online only).Back to article page